Dullard Activators
The group of compounds referred to as Dullard Activators consists of diverse molecules that modulate various cellular pathways to indirectly enhance the activity of CTDNEP1, also known as Dullard. These compounds act on signaling pathways that either directly interact with or are antagonistic to the TGF-beta pathway, which CTDNEP1 negatively regulates. Examples of such pathways include the PI3K/AKT, MEK/ERK, JNK, mTOR, and NF-kappaB pathways. Compounds like LY294002, Wortmannin, PD98059, U0126, Rapamycin, and PDTC inhibit these pathways, potentially leading to anincrease in CTDNEP1's activity. The inhibition of these pathways reduces the antagonistic effects on the TGF-beta pathway, allowing for enhanced CTDNEP1 activity.
In addition to these, the Dullard Activators also include compounds that influence cellular processes indirectly linked to CTDNEP1 activity, such as actin cytoskeleton arrangement. These processes can be modulated by changes in TGF-beta signaling, which is regulated by CTDNEP1. Compounds in this category include Y-27632 and Blebbistatin, which inhibit the ROCK and myosin II proteins respectively. The final set of compounds in the Dullard Activators class are those that inhibit proteins which can activate the TGF-beta pathway. These include KN-93 and RO-3306, which inhibit CaMKII and CDK1 respectively. By inhibiting the activation of the TGF-beta pathway, these compounds indirectly enhance CTDNEP1 activity. The Dullard Activators, therefore, represent a diverse class of compounds that indirectly enhance CTDNEP1 activity through their modulation of various cellular pathways and processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that inhibits the downstream AKT pathway. As CTDNEP1 is known to be a negative regulator of the TGF-beta pathway, which is antagonized by PI3K/AKT, the inhibition of the PI3K/AKT pathway by LY294002 can indirectly enhance the activity of CTDNEP1. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 is a TGF-beta receptor inhibitor. By inhibiting the TGF-beta receptor, it reduces the inhibitory phosphorylation of CTDNEP1, hence potentially increasing its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. The JNK pathway can be activated by TGF-beta signaling, which CTDNEP1 negatively regulates. Inhibition of JNK signaling by SP600125 can indirectly enhance CTDNEP1 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor. The MEK/ERK pathway can be activated by TGF-beta signaling, which CTDNEP1 negatively regulates. Inhibition of MEK signaling by PD98059 can indirectly enhance CTDNEP1 activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor. ROCK is involved in actin cytoskeleton arrangement, a process that may be indirectly influenced by CTDNEP1 as its activity impacts Smad protein availability, key mediators of TGF-beta signaling, which can influence the actin cytoskeleton. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor. By inhibiting the PI3K/AKT pathway, which antagonizes the TGF-beta pathway that CTDNEP1 negatively regulates, Wortmannin can indirectly enhance CTDNEP1 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. mTOR signaling can antagonize TGF-beta signaling, which is negatively regulated by CTDNEP1. By inhibiting mTOR signaling, Rapamycin may indirectly increase the activity of CTDNEP1. | ||||||
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $179.00 $307.00 $455.00 $924.00 $1689.00 | 7 | |
Blebbistatin is a myosin II inhibitor. Myosin II is involved in actin cytoskeleton arrangement, a process that may be indirectly influenced by CTDNEP1 through its activity impacting TGF-beta signaling. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
KN-93 is a CaMKII inhibitor. CaMKII can activate the TGF-beta pathway, which is negatively regulated by CTDNEP1. By inhibiting CaMKII, KN-93 might indirectly enhance CTDNEP1 activity. | ||||||
Pyrrolidinedithiocarbamic acid ammonium salt | 5108-96-3 | sc-203224 sc-203224A | 5 g 25 g | $32.00 $63.00 | 11 | |
PDTC is a NF-kappaB inhibitor. NF-kappaB can antagonize TGF-beta signaling, which is negatively regulated by CTDNEP1. By inhibiting NF-kappaB, PDTC can indirectly enhance CTDNEP1 activity. | ||||||